Literature DB >> 19266613

Lubiprostone: clinical applications beyond constipation.

Shailendra Kapoor.   

Abstract

In comparison to polyethylene glycol, lubiprostone offers other advantages and is increasingly being used as an adjunctive agent in diagnostic as well as management strategies not only in gastroenterology, but in other fields. For instance, lubiprostone exerts beneficial effects in cystic fibrosis tissues. It augments the chloride secretion in these cells by activating non-cystic fibrosis transmembrane regulator (CFTR) secretion of chloride by afflicted respiratory epithelia. Lubiprostone also seems to improve visualization of the gastrointestinal tract during procedures such as colonoscopy. This is especially true if the lubiprostone is administered prior to bowel cleansing with agents such as polyethylene glycol electrolyte (PEG-E). Lubiprostone also enhances and stimulates contraction in colonic as well as gastric muscles and may thus further contribute as a prokinetic agent. Besides these effects, lubiprostone also causes hyperpolarization in other tissues such as uterine muscle cells. This may prove to be of significant clinical benefit in the management of uterine pathologies in the near future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19266613      PMCID: PMC2655180          DOI: 10.3748/wjg.15.1147

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  5 in total

1.  Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice.

Authors:  Kelvin D MacDonald; Karen R McKenzie; Mark J Henderson; Charles E Hawkins; Neeraj Vij; Pamela L Zeitlin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-09-19       Impact factor: 5.464

2.  Single-dose lubiprostone along with split-dose PEG solution without dietary restrictions for bowel cleansing prior to colonoscopy: a randomized, double-blind, placebo-controlled trial.

Authors:  Joel Z Stengel; David P Jones
Journal:  Am J Gastroenterol       Date:  2008-08-05       Impact factor: 10.864

3.  Effects of lubiprostone on human uterine smooth muscle cells.

Authors:  John Cuppoletti; Danuta H Malinowska; Jayati Chakrabarti; Ryuji Ueno
Journal:  Prostaglandins Other Lipid Mediat       Date:  2008-03-22       Impact factor: 3.072

4.  Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon.

Authors:  A K Bassil; R A Borman; E M Jarvie; R J McArthur-Wilson; R Thangiah; E Z H Sung; K Lee; G J Sanger
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

5.  Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.

Authors:  Adam-J Moeser; Prashant-K Nighot; Birgit Roerig; Ryuji Ueno; Anthony-T Blikslager
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

  5 in total
  3 in total

Review 1.  Lubiprostone in constipation: clinical evidence and place in therapy.

Authors:  Nicholas Wilson; Ron Schey
Journal:  Ther Adv Chronic Dis       Date:  2015-03       Impact factor: 5.091

Review 2.  Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome.

Authors:  Ron Schey; Satish S C Rao
Journal:  Dig Dis Sci       Date:  2011-04-27       Impact factor: 3.199

3.  A meta-analysis of randomized controlled trials of the addition of lubiprostone to bowel preparation before colonoscopy.

Authors:  Peng Li; Xue-Qian He; Jie Dong; Jing Du
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.